Literature DB >> 29054425

Molecular characterization of congenital myasthenic syndromes in Spain.

D Natera-de Benito1, A Töpf2, J J Vilchez3, L González-Quereda4, J Domínguez-Carral5, J Díaz-Manera6, C Ortez7, M Bestué8, P Gallano4, M Dusl9, A Abicht10, J S Müller11, J Senderek9, A García-Ribes12, N Muelas3, T Evangelista2, Y Azuma2, G McMacken2, A Paipa Merchan13, P M Rodríguez Cruz14, A Camacho15, E Jiménez16, M C Miranda-Herrero17, A Santana-Artiles18, O García-Campos19, R Dominguez-Rubio13, M Olivé13, J Colomer7, D Beeson14, H Lochmüller2, A Nascimento7.   

Abstract

Congenital myasthenic syndromes (CMS) are a heterogeneous group of genetic disorders, all of which impair neuromuscular transmission. Epidemiological data and frequencies of gene mutations are scarce in the literature. Here we describe the molecular genetic and clinical findings of sixty-four genetically confirmed CMS patients from Spain. Thirty-six mutations in the CHRNE, RAPSN, COLQ, GFPT1, DOK7, CHRNG, GMPPB, CHAT, CHRNA1, and CHRNB1 genes were identified in our patients, with five of them not reported so far. These data provide an overview on the relative frequencies of the different CMS subtypes in a large Spanish population. CHRNE mutations are the most common cause of CMS in Spain, accounting for 27% of the total. The second most common are RAPSN mutations. We found a higher rate of GFPT1 mutations in comparison with other populations. Remarkably, several founder mutations made a large contribution to CMS in Spain: RAPSN c.264C > A (p.Asn88Lys), CHRNE c.130insG (Glu44Glyfs*3), CHRNE c.1353insG (p.Asn542Gluf*4), DOK7 c.1124_1127dup (p.Ala378Serfs*30), and particularly frequent in Spain in comparison with other populations, COLQ c.1289A > C (p.Tyr430Ser). Furthermore, we describe phenotypes and distinguishing clinical signs associated with the various CMS genes which might help to identify specific CMS subtypes to guide diagnosis and management.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CHRNE; COLQ; Congenital myasthenic syndrome; DOK7; GFPT1; GMPPB; Genetic mutations; RAPSN; Slow-channel syndrome

Mesh:

Year:  2017        PMID: 29054425     DOI: 10.1016/j.nmd.2017.08.003

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  13 in total

1.  Clinicopathological-genetic features of congenital myasthenic syndrome from a Chinese neuromuscular centre.

Authors:  Kun Huang; Hui-Qian Duan; Qiu-Xiang Li; Yue-Bei Luo; Fang-Fang Bi; Huan Yang
Journal:  J Cell Mol Med       Date:  2022-06-06       Impact factor: 5.295

2.  A common CHRNE mutation in Brazilian patients with congenital myasthenic syndrome.

Authors:  Eduardo de Paula Estephan; Cláudia Ferreira da Rosa Sobreira; André Clériston José Dos Santos; Pedro José Tomaselli; Wilson Marques; Roberta Paiva Magalhães Ortega; Marcela Câmara Machado Costa; André Macedo Serafim da Silva; Rodrigo Holanda Mendonça; Vitor Marques Caldas; Antonio Alberto Zambon; Osório Abath Neto; Paulo Eurípedes Marchiori; Carlos Otto Heise; Umbertina Conti Reed; Yoshiteru Azuma; Ana Töpf; Hanns Lochmüller; Edmar Zanoteli
Journal:  J Neurol       Date:  2018-01-30       Impact factor: 4.849

3.  Congenital myasthenic syndromes in adult neurology clinic: A long road to diagnosis and therapy.

Authors:  Justin C Kao; Margherita Milone; Duygu Selcen; Xin-Ming Shen; Andrew G Engel; Teerin Liewluck
Journal:  Neurology       Date:  2018-10-05       Impact factor: 9.910

4.  Mitochondrial disorder mimicking rheumatoid disease.

Authors:  Josef Finsterer; Madleine Melichart-Kotig; Adelheid Woehrer
Journal:  Z Rheumatol       Date:  2019-11       Impact factor: 1.372

5.  Profile of the Nicotinic Cholinergic Receptor Alpha 7 Subunit Gene Expression is Associated with Response to Varenicline Treatment.

Authors:  Juliana Rocha Santos; Paulo Roberto Xavier Tomaz; Jaqueline Ribeiro Scholz; Patrícia Viviane Gaya; Tânia Ogawa Abe; José Eduardo Krieger; Alexandre Costa Pereira; Paulo Caleb Júnior de Lima Santos
Journal:  Genes (Basel)       Date:  2020-07-06       Impact factor: 4.096

6.  Long Term Follow-Up on Pediatric Cases With Congenital Myasthenic Syndromes-A Retrospective Single Centre Cohort Study.

Authors:  Adela Della Marina; Eva Wibbeler; Angela Abicht; Heike Kölbel; Hanns Lochmüller; Andreas Roos; Ulrike Schara
Journal:  Front Hum Neurosci       Date:  2020-12-07       Impact factor: 3.169

7.  Congenital myasthenic syndrome in China: genetic and myopathological characterization.

Authors:  Yawen Zhao; Ying Li; Yang Bian; Sheng Yao; Penju Liu; Meng Yu; Wei Zhang; Zhaoxia Wang; Yun Yuan
Journal:  Ann Clin Transl Neurol       Date:  2021-03-23       Impact factor: 4.511

8.  Congenital Myasthenic Syndrome Caused by a Novel Hemizygous CHAT Mutation.

Authors:  Yixia Zhang; Xinru Cheng; Chenghan Luo; Mengyuan Lei; Fengxia Mao; Zanyang Shi; Wenjun Cao; Jingdi Zhang; Qian Zhang
Journal:  Front Pediatr       Date:  2020-04-28       Impact factor: 3.418

Review 9.  Limb-girdle muscular dystrophy due to GMPPB mutations: A case report and comprehensive literature review.

Authors:  LiuQing Sun; DingGuo Shen; Ting Xiong; Zhibin Zhou; Xianghui Lu; Fang Cui
Journal:  Bosn J Basic Med Sci       Date:  2020-05-01       Impact factor: 3.363

10.  Clinical and electrophysiological evaluation of myasthenic features in an alpha-dystroglycanopathy cohort (FKRP-predominant).

Authors:  Paloma Gonzalez-Perez; Cheryl Smith; Wendy L Sebetka; Amber Gedlinske; Seth Perlman; Katherine D Mathews
Journal:  Neuromuscul Disord       Date:  2020-01-25       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.